In the present study, we demonstrate that CRISPR/Cas13-mediated knockdown of Frmd4a, a factor associated with brain developmental disorders and a known risk factor for Alzheimer’s disease, or its homolog Frmd4b, results in decreased process elongation and decreased neuronal marker expression in cells. This evidence concerns the gene FRMD4A and early-onset autosomal dominant Alzheimer disease.